News Conference News SCCT 2024 Should Coronary Calcium Always Be Noted on Noncardiac CT Reports? Todd Neale July 24, 2024
News Conference News AHA 2023 Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV Todd Neale November 17, 2023
News Conference News ACC 2023 Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III Shelley Wood March 04, 2023
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News ACC 2022 PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI Todd Neale April 03, 2022
News Conference News TCT 2020 Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB Michael O'Riordan October 14, 2020
News Conference News ESC 2017 CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events Michael O'Riordan August 27, 2017
News Conference News SCCT 2017 Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See? Yael L. Maxwell July 10, 2017
News Conference News ESC 2016 When Unblinded to Statin Therapy, Patients’ Muscle-Related Adverse Events Shoot Up: ASCOT Analysis Michael O'Riordan August 31, 2016
News Conference News ESC 2016 Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER Michael O'Riordan August 30, 2016
News Conference News ESC 2016 Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say Michael O'Riordan August 27, 2016
News Conference News EAS 2016 Non-HDL Cholesterol, Inflammation Appear to Be Linked in Patients Undergoing Elective PCI Yael L. Maxwell June 08, 2016
News Conference News EAS 2016 Preservation of LDL Cholesterol Targets for Lipid Lowering in New European Guidance Gets Blessing of Prevention Experts Yael L. Maxwell June 06, 2016
News Conference News EuroPCR 2016 Stent ‘Sealing’ of Nonobstructive Saphenous Vein Graft Plaques Fails to Prevent CV Events Shelley Wood May 18, 2016
News Conference News ACC 2016 Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH Michael O'Riordan April 03, 2016